Craig Drill Capital Boosts Stake in Syneron Medical to 5.17%
Craig Drill Capital‘s stake in Syneron Medical Ltd. (NASDAQ:ELOS) has gone up according to a new 13G filing with the SEC. Managed by Craig A. Drill, the fund’s holding of the stock stood at 160,000 Ordinary Shares at the end of the June quarter and has now climbed to 1.82 million Ordinary Shares or 5.17% of Syneron Medical’s outstanding stock.
Syneron Medical Ltd. (NASDAQ:ELOS) is a company that produces various products for the medical aesthetic industry. Since the beginning of the year, the company’s stock has lost 1.43%. Recently, the company announced its preliminary financial results for the third quarter, with it announcing that revenue should reach $70 million-to-$72 million; its complete results are scheduled for release on November 9.
At the end of June, 14 smart money managers from within our database were long Syneron Medical Ltd. (NASDAQ:ELOS), same as a quarter earlier. Among the bullish investors were Richard Mashaal’s RIMA Senvest Management, which held $29.56 million worth of Syneron Medical’s shares.
Billionaire Mario Gabelli’s GAMCO Investors Slightly Lowers Its Stake in Bioscrip
Billionaire Mario Gabelli‘s GAMCO Investors recently filed an amended Form 13D with the Securities and Exchange Commission in which it reported slightly lowering its stake in Bioscrip Inc. (NASDAQ:BIOS). The fund, together with its affiliates, holds 15.53 million shares of the company, which amass 13.19% of the float, while GAMCO solely owns 866,402 shares or 0.74% of the outstanding stock. According to its 13F filing for the June 30 reporting period, GAMCO held 904,402 Bioscrip common shares.
Bioscrip Inc. (NASDAQ:BIOS) is a company that provides infusion and home care management solutions, working with healthcare facilities and medical professionals. Over the past 12 months, the company’s shares have gained a robust 78.57%. For the second quarter of 2016, Bioscrip reported a loss per share of $0.14, and revenue of $232.46 million, compared to a loss per share of $3.63 and revenue of $246.9 million for the corresponding quarter of 2015.
According to Insider Monkey’s hedge fund database, 23 investors in it reported having long positions in Bioscrip Inc. (NASDAQ:BIOS) as of the end of June, up by ten from the end of the previous quarter. Among the bullish investors were Stephen Dubois’ Camber Capital Management, which held a position valued at $25.96 million, Ric Dillon’s Diamond Hill Capital, with a position worth $13.56 million, Phil Frohlich’s Prescott Group Capital Management, and Ken Griffin’s Citadel Investment Group.
Disclosure: None
